New guidance addresses Australian firms' worries over post-market reviews
This article was originally published in Scrip
Executive Summary
A new version of the Australian framework for post-market reviews, which are used to monitor marketed medicines in order to improve the quality of their use and help ensure the sustainability of the Pharmaceutical Benefits Scheme, is expected to be published soon following its adoption by the government and the pharmaceutical industry.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.